Acura NanoMedicine Corporation
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. Out-licensing of innovative drug products, including the AN-8 series, a novel therapy designed to reverse cancer drug resistance, and other pharmaceuticals.
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2
The content above was translated by Ai
Founded Year
2017
Unified Business No.
52805302
Status
Active
Number of Employees
4
Total Paid-in
Capital
25,014,700 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Acura NanoMedicine is one of the few dual-platform technology new drug companies in the world. We integrate AI big data drug discovery platform and nano drug delivery system platform to develop a series of nano anticancer drugs (AN-8 series & others) that are highly effective to overcome a variety of difficult-to-treat cancers such as drug-resistant pancreatic cancer/brain cancer, etc. At the same time, we also use our platform technologies to cooperate with other new drug companies to form a joint development network for co-development new drugs.
The content above was translated by Ai
